New hope for tough lymphoma: drug combo aims to boost transplant success
NCT ID NCT07365306
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial tests whether adding the immunotherapy epcoritamab to standard chemo (R-GemOx) before an autologous stem cell transplant can improve outcomes for people with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). The study enrolls 43 adults whose lymphoma has returned or not responded to prior treatment. Epcoritamab works by bringing immune T cells close to lymphoma cells to kill them, while the chemo helps clear the cancer before transplant.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Epcoritamab (a bispecific antibody) combined with rituximab, gemcitabine, and oxaliplatin (chemotherapy), followed by an autologous stem cell transplant
- What this could lead to
- If successful, this combination could offer a more effective salvage therapy before stem cell transplant, potentially improving remission rates for patients with hard-to-treat DLBCL.
- What could go wrong
- This is a small, early-phase (Phase 2) trial with only 43 participants, so results may not apply broadly. The treatment involves strong chemotherapy and stem cell transplant, which carry risks like infection and organ damage.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT DIFFUSE LARGE B-CELL LYMPHOMA, NOT OTHERWISE SPECIFIED are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
City of Hope Atlanta Cancer Center
NOT_YET_RECRUITINGNewnan, Georgia, 30265, United States
-
City of Hope Medical Center
RECRUITINGDuarte, California, 91010, United States
-
City of Hope at Chicago
NOT_YET_RECRUITINGZion, Illinois, 60099, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New combo therapy aims to stop aggressive lymphoma relapse
- New drug cocktail aims to outsmart Hard-to-Treat lymphoma
- New drug duo aims to outsmart tough lymphoma
- New drug cocktail aims to rescue patients from Hard-to-Treat lymphoma
- Immunotherapy duo takes on tough lymphomas
- New combo may help more lymphoma patients reach potentially curative CAR-T